Iovance Biotherapeutics, Inc. (IOVA)
USD 3.02
(-7.08%)
USD 3.02
(-7.08%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 780.35 Million USD | 17.53% |
| 2022 | 663.98 Million USD | -14.58% |
| 2021 | 777.33 Million USD | 1.15% |
| 2020 | 768.45 Million USD | 122.96% |
| 2019 | 344.65 Million USD | -28.32% |
| 2018 | 480.82 Million USD | 209.46% |
| 2017 | 155.37 Million USD | -9.61% |
| 2016 | 171.88 Million USD | 62.69% |
| 2015 | 105.65 Million USD | 127.18% |
| 2014 | 46.5 Million USD | 134.01% |
| 2013 | 19.87 Million USD | 67467.57% |
| 2012 | 29.41 Thousand USD | -94.83% |
| 2011 | 568.43 Thousand USD | -61.09% |
| 2010 | 1.46 Million USD | 15067.69% |
| 2009 | 9632.00 USD | 71.63% |
| 2008 | 5612.00 USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 964.32 Million USD | 10.86% |
| 2024 Q1 | 869.83 Million USD | 11.47% |
| 2023 Q4 | 780.35 Million USD | -8.44% |
| 2023 FY | 780.35 Million USD | 17.53% |
| 2023 Q3 | 852.31 Million USD | 12.55% |
| 2023 Q2 | 757.29 Million USD | -8.18% |
| 2023 Q1 | 824.76 Million USD | 24.22% |
| 2022 Q4 | 663.98 Million USD | 21.63% |
| 2022 Q3 | 545.92 Million USD | -10.63% |
| 2022 FY | 663.98 Million USD | -14.58% |
| 2022 Q1 | 701.25 Million USD | -9.79% |
| 2022 Q2 | 610.87 Million USD | -12.89% |
| 2021 Q3 | 828.82 Million USD | -2.81% |
| 2021 Q2 | 852.79 Million USD | 13.62% |
| 2021 Q4 | 777.33 Million USD | -6.21% |
| 2021 Q1 | 750.57 Million USD | -2.33% |
| 2021 FY | 777.33 Million USD | 1.15% |
| 2020 Q3 | 782.29 Million USD | -4.31% |
| 2020 FY | 768.45 Million USD | 122.96% |
| 2020 Q2 | 817.56 Million USD | 183.58% |
| 2020 Q4 | 768.45 Million USD | -1.77% |
| 2020 Q1 | 288.29 Million USD | -16.35% |
| 2019 FY | 344.65 Million USD | -28.32% |
| 2019 Q1 | 461.5 Million USD | -4.02% |
| 2019 Q2 | 435.92 Million USD | -5.54% |
| 2019 Q3 | 395.74 Million USD | -9.22% |
| 2019 Q4 | 344.65 Million USD | -12.91% |
| 2018 FY | 480.82 Million USD | 209.46% |
| 2018 Q4 | 480.82 Million USD | 77.53% |
| 2018 Q3 | 270.83 Million USD | -4.89% |
| 2018 Q2 | 284.75 Million USD | -7.32% |
| 2018 Q1 | 307.24 Million USD | 97.75% |
| 2017 FY | 155.37 Million USD | -9.61% |
| 2017 Q4 | 155.37 Million USD | -10.69% |
| 2017 Q3 | 173.97 Million USD | 26.05% |
| 2017 Q2 | 138.01 Million USD | -11.18% |
| 2017 Q1 | 155.38 Million USD | -9.6% |
| 2016 Q3 | 182.32 Million USD | -5.8% |
| 2016 FY | 171.88 Million USD | 62.69% |
| 2016 Q2 | 193.54 Million USD | 92.07% |
| 2016 Q4 | 171.88 Million USD | -5.73% |
| 2016 Q1 | 100.76 Million USD | -4.62% |
| 2015 Q3 | 112.22 Million USD | -2.19% |
| 2015 FY | 105.65 Million USD | 127.18% |
| 2015 Q4 | 105.65 Million USD | -5.86% |
| 2015 Q2 | 114.73 Million USD | 1.06% |
| 2015 Q1 | 113.53 Million USD | 144.13% |
| 2014 Q2 | 18.53 Million USD | 2.5% |
| 2014 Q1 | 18.08 Million USD | -9.01% |
| 2014 FY | 46.5 Million USD | 134.01% |
| 2014 Q4 | 46.5 Million USD | 167.02% |
| 2014 Q3 | 17.41 Million USD | -6.03% |
| 2013 Q1 | 28.33 Thousand USD | -3.67% |
| 2013 Q3 | 168.62 Thousand USD | -71.79% |
| 2013 Q2 | 597.74 Thousand USD | 2009.73% |
| 2013 Q4 | 19.87 Million USD | 11685.64% |
| 2013 FY | 19.87 Million USD | 67467.57% |
| 2012 FY | 29.41 Thousand USD | -94.83% |
| 2012 Q1 | 76.84 Thousand USD | -86.48% |
| 2012 Q2 | 65.61 Thousand USD | -14.62% |
| 2012 Q3 | 28.69 Thousand USD | -56.27% |
| 2012 Q4 | 29.41 Thousand USD | 2.51% |
| 2011 FY | 568.43 Thousand USD | -61.09% |
| 2011 Q2 | 466.16 Thousand USD | -49.89% |
| 2011 Q4 | 568.43 Thousand USD | -83.47% |
| 2011 Q1 | 930.2 Thousand USD | -36.33% |
| 2011 Q3 | 3.43 Million USD | 637.63% |
| 2010 Q3 | 1.02 Million USD | 135.22% |
| 2010 Q4 | 1.46 Million USD | 43.2% |
| 2010 Q1 | 536.43 Thousand USD | 5469.33% |
| 2010 Q2 | 433.72 Thousand USD | -19.15% |
| 2010 FY | 1.46 Million USD | 15067.69% |
| 2009 Q3 | 2477.00 USD | -25.99% |
| 2009 Q4 | 9632.00 USD | 288.86% |
| 2009 Q2 | 3347.00 USD | -15.09% |
| 2009 Q1 | 3942.00 USD | -29.76% |
| 2009 FY | 9632.00 USD | 71.63% |
| 2008 Q1 | 35.95 Thousand USD | 0.0% |
| 2008 Q4 | 5612.00 USD | -71.65% |
| 2008 Q2 | 21.11 Thousand USD | -41.28% |
| 2008 Q3 | 19.79 Thousand USD | -6.26% |
| 2008 FY | 5612.00 USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AbCellera Biologics Inc. | 1.48 Billion USD | 47.56% |
| Alkermes plc | 2.13 Billion USD | 63.471% |
| Agenus Inc. | 313.91 Million USD | -148.588% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 79.625% |
| Aptorum Group Limited | 20.64 Million USD | -3680.754% |
| Ardelyx, Inc. | 297.57 Million USD | -162.233% |
| Arrowhead Pharmaceuticals, Inc. | 765.55 Million USD | -1.933% |
| Bicycle Therapeutics plc | 595.34 Million USD | -31.076% |
| BioXcel Therapeutics, Inc. | 73.7 Million USD | -958.792% |
| ChromaDex Corporation | 54.96 Million USD | -1319.749% |
| Chimerix, Inc. | 212.77 Million USD | -266.751% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -2660.117% |
| Caribou Biosciences, Inc. | 440.96 Million USD | -76.963% |
| CRISPR Therapeutics AG | 2.22 Billion USD | 65.0% |
| Precision BioSciences, Inc. | 159.78 Million USD | -388.388% |
| Dyadic International, Inc. | 8.21 Million USD | -9394.204% |
| Eton Pharmaceuticals, Inc. | 31.74 Million USD | -2358.573% |
| Fortress Biotech, Inc. | 167.52 Million USD | -365.809% |
| Lantern Pharma Inc. | 43.64 Million USD | -1687.843% |
| HOOKIPA Pharma Inc. | 161.33 Million USD | -383.678% |
| Inhibikase Therapeutics, Inc. | 14.5 Million USD | -5279.265% |
| Incyte Corporation | 6.78 Billion USD | 88.494% |
| IO Biotech, Inc. | 150.71 Million USD | -417.756% |
| Jaguar Health, Inc. | 50.76 Million USD | -1437.244% |
| Novavax, Inc. | 1.85 Billion USD | 57.94% |
| Janux Therapeutics, Inc. | 380.4 Million USD | -105.136% |
| Opthea Limited | 188.79 Million USD | -313.341% |
| Ligand Pharmaceuticals Incorporated | 833.06 Million USD | 6.328% |
| ContextLogic Inc. | 423 Million USD | -84.48% |
| MiMedx Group, Inc. | 239.04 Million USD | -226.442% |
| Pyxis Oncology, Inc. | 173.72 Million USD | -349.185% |
| TransCode Therapeutics, Inc. | 5.16 Million USD | -14994.703% |
| NextCure, Inc. | 129.41 Million USD | -502.969% |
| Ocuphire Pharma, Inc. | 53.94 Million USD | -1346.487% |
| Oncternal Therapeutics, Inc. | 36.72 Million USD | -2024.618% |
| Outlook Therapeutics, Inc. | 32.3 Million USD | -2315.873% |
| Vaxcyte, Inc. | 1.4 Billion USD | 44.574% |
| PDS Biotechnology Corporation | 59.39 Million USD | -1213.942% |
| Madrigal Pharmaceuticals, Inc. | 640.54 Million USD | -21.826% |
| Pharming Group N.V. | 462.85 Million USD | -68.595% |
| Pieris Pharmaceuticals, Inc. | 38.68 Million USD | -1917.453% |
| Avidity Biosciences, Inc. | 628.55 Million USD | -24.15% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -4023.676% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -4023.676% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -372.025% |
| Sol-Gel Technologies Ltd. | 45.28 Million USD | -1623.124% |
| Acelyrin, Inc. | 742.69 Million USD | -5.071% |
| Salarius Pharmaceuticals, Inc. | 6.58 Million USD | -11747.693% |
| SELLAS Life Sciences Group, Inc. | 6.4 Million USD | -12087.272% |
| Summit Therapeutics Inc. | 202.94 Million USD | -284.506% |
| Sensei Biotherapeutics, Inc. | 74.37 Million USD | -949.226% |
| Senti Biosciences, Inc. | 119.48 Million USD | -553.101% |
| Stoke Therapeutics, Inc. | 228.34 Million USD | -241.747% |
| Syros Pharmaceuticals, Inc. | 168.17 Million USD | -364.014% |
| Alaunos Therapeutics, Inc. | 8.26 Million USD | -9343.919% |
| Telomir Pharmaceuticals, Inc. Common Stock | 4.77 Million USD | -16246.647% |
| Entrada Therapeutics, Inc. | 469.19 Million USD | -66.318% |
| VistaGen Therapeutics, Inc. | 123.65 Million USD | -531.081% |
| Wave Life Sciences Ltd. | 274.94 Million USD | -183.817% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | -65.035% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | -7622.425% |
| Barinthus Biotherapeutics plc | 214.5 Million USD | -263.79% |
| Psyence Biomedical Ltd. | 1.13 Million USD | -68825.919% |
| Phathom Pharmaceuticals, Inc. | 413.84 Million USD | -88.563% |
| Immix Biopharma, Inc. | 19.92 Million USD | -3816.41% |
| Keros Therapeutics, Inc. | 370.02 Million USD | -110.891% |
| MEI Pharma, Inc. | 41.37 Million USD | -1786.045% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -2308.045% |
| Xeris Biopharma Holdings, Inc. | 340.79 Million USD | -128.978% |
| Rigel Pharmaceuticals, Inc. | 117.22 Million USD | -565.687% |
| Fortress Biotech, Inc. | 167.52 Million USD | -365.809% |
| Precigen, Inc. | 151.04 Million USD | -416.642% |
| Clearside Biomedical, Inc. | 34.01 Million USD | -2193.936% |
| AlloVir, Inc. | 190.79 Million USD | -308.998% |
| C4 Therapeutics, Inc. | 376.45 Million USD | -107.292% |
| Fate Therapeutics, Inc. | 506.21 Million USD | -54.153% |
| ImmuCell Corporation | 43.8 Million USD | -1681.294% |
| IDEAYA Biosciences, Inc. | 649.31 Million USD | -20.18% |
| Onconetix, Inc. | 88.82 Million USD | -778.561% |
| PureTech Health plc | 693.97 Million USD | -12.447% |
| VYNE Therapeutics Inc. | 97.68 Million USD | -698.844% |
| Elevation Oncology, Inc. | 89.09 Million USD | -775.903% |
| Kintara Therapeutics, Inc. | 6.2 Million USD | -12482.248% |
| Seer, Inc. | 436.26 Million USD | -78.869% |
| Verrica Pharmaceuticals Inc. | 81.59 Million USD | -856.348% |
| Innoviva, Inc. | 1.24 Billion USD | 37.246% |
| Aadi Bioscience, Inc. | 132.42 Million USD | -489.287% |
| ESSA Pharma Inc. | 149.12 Million USD | -423.297% |
| GlycoMimetics, Inc. | 45.31 Million USD | -1622.003% |
| GT Biopharma, Inc. | 14.1 Million USD | -5430.874% |
| Inhibrx Biosciences, Inc. | 307.89 Million USD | -153.449% |
| Akebia Therapeutics, Inc. | 241.7 Million USD | -222.855% |
| Catalyst Pharmaceuticals, Inc. | 471.9 Million USD | -65.361% |
| Longboard Pharmaceuticals, Inc. | 50.69 Million USD | -1439.245% |
| Orchestra BioMed Holdings, Inc. | 95.21 Million USD | -719.593% |
| Alzamend Neuro, Inc. | 631.58 Thousand USD | -123453.804% |
| Rocket Pharmaceuticals, Inc. | 566.34 Million USD | -37.788% |
| Aptose Biosciences Inc. | 12.92 Million USD | -5938.679% |
| ZyVersa Therapeutics, Inc. | 22.11 Million USD | -3428.719% |
| Soligenix, Inc. | 9.79 Million USD | -7864.939% |
| Century Therapeutics, Inc. | 360.69 Million USD | -116.349% |
| Kura Oncology, Inc. | 448.93 Million USD | -73.823% |
| TScan Therapeutics, Inc. | 272.14 Million USD | -186.737% |
| Intensity Therapeutics, Inc. | 17.29 Million USD | -4412.003% |
| Ocean Biomedical, Inc. | 110.91 Million USD | -603.581% |
| CytomX Therapeutics, Inc. | 205.15 Million USD | -280.379% |
| Autolus Therapeutics plc | 375.38 Million USD | -107.882% |
| Mineralys Therapeutics, Inc. | 251.63 Million USD | -210.111% |
| EyePoint Pharmaceuticals, Inc. | 355.18 Million USD | -119.703% |
| Eterna Therapeutics Inc. | 49.13 Million USD | -1488.274% |
| Adaptive Biotechnologies Corporation | 661.13 Million USD | -18.032% |
| GRI Bio, Inc. | 2.95 Million USD | -26298.884% |
| Xenetic Biosciences, Inc. | 10.6 Million USD | -7258.174% |
| Tenaya Therapeutics, Inc. | 170.51 Million USD | -357.644% |
| IGM Biosciences, Inc. | 423.41 Million USD | -84.301% |
| INmune Bio, Inc. | 57 Million USD | -1269.013% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -250.71% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -829.639% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -2887.921% |
| Entero Therapeutics, Inc. | 6.88 Million USD | -11237.046% |
| Milestone Pharmaceuticals Inc. | 75.22 Million USD | -937.342% |
| X4 Pharmaceuticals, Inc. | 147.25 Million USD | -429.921% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -371.5% |
| Coherus BioSciences, Inc. | 629.6 Million USD | -23.943% |
| Verastem, Inc. | 149.71 Million USD | -421.214% |
| Abeona Therapeutics Inc. | 64 Million USD | -1119.26% |
| Pliant Therapeutics, Inc. | 512.15 Million USD | -52.366% |
| Tonix Pharmaceuticals Holding Corp. | 154.45 Million USD | -405.222% |
| Histogen Inc. | 19.07 Million USD | -3991.391% |
| Aprea Therapeutics, Inc. | 22.65 Million USD | -3345.232% |
| Surrozen, Inc. | 46.08 Million USD | -1593.47% |
| Organovo Holdings, Inc. | 6.34 Million USD | -12190.928% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -18011.391% |
| Ovid Therapeutics Inc. | 144.02 Million USD | -441.81% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | -6512.023% |
| CASI Pharmaceuticals, Inc. | 75.26 Million USD | -936.763% |
| Cadrenal Therapeutics, Inc. Common Stock | 8.51 Million USD | -9059.856% |
| Centessa Pharmaceuticals plc | 362.96 Million USD | -114.991% |
| Hepion Pharmaceuticals, Inc. | 18.09 Million USD | -4212.667% |
| Arcturus Therapeutics Holdings Inc. | 429.4 Million USD | -81.73% |
| BioRestorative Therapies, Inc. | 12.61 Million USD | -6087.507% |
| Apollomics, Inc. | 55.38 Million USD | -1308.906% |
| Amarin Corporation plc | 831.68 Million USD | 6.172% |
| Mesoblast Limited | 669.15 Million USD | -16.618% |
| Turnstone Biologics Corp. | 112.81 Million USD | -591.709% |
| Kymera Therapeutics, Inc. | 575.75 Million USD | -35.534% |
| Synaptogenix, Inc. | 31.11 Million USD | -2408.065% |
| Tiziana Life Sciences Ltd | 12.18 Million USD | -6304.719% |
| Aurinia Pharmaceuticals Inc. | 548.06 Million USD | -42.384% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -13188.766% |
| Monopar Therapeutics Inc. | 7.34 Million USD | -10524.018% |
| Exelixis, Inc. | 2.94 Billion USD | 73.479% |
| Better Therapeutics, Inc. | 22.94 Million USD | -3301.26% |
| Nurix Therapeutics, Inc. | 364.53 Million USD | -114.065% |
| Apellis Pharmaceuticals, Inc. | 788.73 Million USD | 1.062% |
| NLS Pharmaceutics AG | 1.84 Million USD | -42157.862% |
| Dermata Therapeutics, Inc. | 7.97 Million USD | -9680.509% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | -5210.316% |
| Gritstone bio, Inc. | 177.76 Million USD | -338.969% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -718.15% |
| TNF Pharmaceuticals, Inc. | 17.86 Million USD | -4268.711% |
| Avid Bioservices, Inc. | 336.55 Million USD | -131.863% |
| Insmed Incorporated | 1.32 Billion USD | 41.32% |
| Virpax Pharmaceuticals, Inc. | 9.62 Million USD | -8004.726% |
| MediWound Ltd. | 66.45 Million USD | -1074.184% |
| OmniAb, Inc. | 401.98 Million USD | -94.124% |
| Alector, Inc. | 621.82 Million USD | -25.493% |
| Seres Therapeutics, Inc. | 358.6 Million USD | -117.61% |
| Checkpoint Therapeutics, Inc. | 5.37 Million USD | -14410.06% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | -1276.475% |
| Zai Lab Limited | 1.03 Billion USD | 24.698% |
| Revance Therapeutics, Inc. | 478.45 Million USD | -63.098% |
| Aura Biosciences, Inc. | 255.07 Million USD | -205.93% |
| Lyell Immunopharma, Inc. | 750.02 Million USD | -4.043% |
| Immunic, Inc. | 54.29 Million USD | -1337.137% |
| Tarsus Pharmaceuticals, Inc. | 266.22 Million USD | -193.118% |
| Veracyte, Inc. | 1.13 Billion USD | 31.417% |
| InMed Pharmaceuticals Inc. | 11.82 Million USD | -6500.401% |
| FibroGen, Inc. | 423.52 Million USD | -84.25% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -22113.237% |
| Adial Pharmaceuticals, Inc. | 4.73 Million USD | -16374.901% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.42 Million USD | -14272.487% |
| Jazz Pharmaceuticals plc | 11.39 Billion USD | 93.151% |
| Cyclacel Pharmaceuticals, Inc. | 8.8 Million USD | -8762.589% |
| Amylyx Pharmaceuticals, Inc. | 517.45 Million USD | -50.806% |
| TG Therapeutics, Inc. | 329.58 Million USD | -136.766% |
| Galecto, Inc. | 38.22 Million USD | -1941.361% |
| Calithera Biosciences, Inc. | 28.67 Million USD | -2621.269% |
| Fortrea Holdings Inc. | 4.35 Billion USD | 82.091% |
| KalVista Pharmaceuticals, Inc. | 235.4 Million USD | -231.494% |
| Aptevo Therapeutics Inc. | 24.84 Million USD | -3041.257% |
| XBiotech Inc. | 227.24 Million USD | -243.399% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -718.15% |
| Lyra Therapeutics, Inc. | 142.6 Million USD | -447.231% |
| Foghorn Therapeutics Inc. | 285.91 Million USD | -172.93% |
| Y-mAbs Therapeutics, Inc. | 127.86 Million USD | -510.274% |
| Theravance Biopharma, Inc. | 381.99 Million USD | -104.281% |
| Ultragenyx Pharmaceutical Inc. | 1.49 Billion USD | 47.663% |
| Metagenomi, Inc. Common Stock | 364.84 Million USD | -113.887% |
| Vaxxinity, Inc. | 44.35 Million USD | -1659.41% |
| BioCryst Pharmaceuticals, Inc. | 516.96 Million USD | -50.95% |
| Gain Therapeutics, Inc. | 18.6 Million USD | -4093.332% |
| Cartesian Therapeutics, Inc. | 305.05 Million USD | -155.811% |
| NexImmune, Inc. | 8.59 Million USD | -8980.238% |
| Creative Medical Technology Holdings, Inc. | 10.71 Million USD | -7182.661% |
| Marker Therapeutics, Inc. | 17.12 Million USD | -4456.158% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 97.641% |
| Chemomab Therapeutics Ltd. | 22.15 Million USD | -3422.849% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | -198834.649% |
| RAPT Therapeutics, Inc. | 173.32 Million USD | -350.214% |
| Ainos, Inc. | 31.84 Million USD | -2350.712% |
| Pluri Inc. | 39.52 Million USD | -1874.223% |
| Prothena Corporation plc | 696.38 Million USD | -12.058% |
| Adaptimmune Therapeutics plc | 282.61 Million USD | -176.117% |
| Celularity Inc. | 143.88 Million USD | -442.328% |
| Rallybio Corporation | 115.62 Million USD | -574.927% |
| Cue Biopharma, Inc. | 61.53 Million USD | -1168.245% |
| MeiraGTx Holdings plc | 458.16 Million USD | -70.32% |
| Omeros Corporation | 378.26 Million USD | -106.295% |
| Humacyte, Inc. | 128.22 Million USD | -508.589% |
| Immunocore Holdings plc | 597 Million USD | -30.712% |
| Cocrystal Pharma, Inc. | 31.25 Million USD | -2396.404% |
| Cidara Therapeutics, Inc. | 68.53 Million USD | -1038.7% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 25.628% |
| CalciMedica, Inc. | 12.18 Million USD | -6304.194% |
| Cabaletta Bio, Inc. | 253.65 Million USD | -207.649% |
| Marinus Pharmaceuticals, Inc. | 170.9 Million USD | -356.591% |
| Scholar Rock Holding Corporation | 311.03 Million USD | -150.888% |
| Sana Biotechnology, Inc. | 565.29 Million USD | -38.042% |
| Pulmatrix, Inc. | 33.95 Million USD | -2197.989% |
| Elicio Therapeutics, Inc. | 27.14 Million USD | -2774.645% |
| Vigil Neuroscience, Inc. | 140.85 Million USD | -453.998% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 40.018% |
| Adlai Nortye Ltd. American Depositary Shares | 130.18 Million USD | -499.398% |
| Cytokinetics, Incorporated | 824.31 Million USD | 5.334% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | -3594.319% |
| Nutriband Inc. | 7.51 Million USD | -10280.937% |
| Protara Therapeutics, Inc. | 78.95 Million USD | -888.362% |
| Vor Biopharma Inc. | 209.82 Million USD | -271.9% |
| Roivant Sciences Ltd. | 7.22 Billion USD | 89.196% |
| Evogene Ltd. | 51.1 Million USD | -1427.076% |
| ProKidney Corp. | 420.55 Million USD | -85.554% |
| Applied Therapeutics, Inc. | 54.83 Million USD | -1323.141% |
| Hoth Therapeutics, Inc. | 9.52 Million USD | -8096.725% |
| BridgeBio Pharma, Inc. | 546.38 Million USD | -42.822% |
| CorMedix Inc. | 82.05 Million USD | -850.952% |
| BioLineRx Ltd. | 63.92 Million USD | -1120.729% |
| Tango Therapeutics, Inc. | 402.56 Million USD | -93.844% |
| Galectin Therapeutics Inc. | 28.2 Million USD | -2667.202% |
| Atai Life Sciences N.V. | 293.47 Million USD | -165.898% |
| Renovaro Biosciences Inc. | 163.12 Million USD | -378.363% |
| Aerovate Therapeutics, Inc. | 127.41 Million USD | -512.434% |
| Zentalis Pharmaceuticals, Inc. | 562.02 Million USD | -38.846% |
| Sagimet Biosciences Inc. | 96.71 Million USD | -706.823% |
| MediciNova, Inc. | 66.26 Million USD | -1077.533% |
| Praxis Precision Medicines, Inc. | 87.94 Million USD | -787.287% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -17387.386% |
| GeoVax Labs, Inc. | 9.28 Million USD | -8306.039% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | -32.66% |
| Biomea Fusion, Inc. | 199.92 Million USD | -290.318% |
| PTC Therapeutics, Inc. | 1.9 Billion USD | 58.998% |
| Mereo BioPharma Group plc | 66.49 Million USD | -1073.478% |
| Cullinan Oncology, Inc. | 485.09 Million USD | -60.865% |
| Syndax Pharmaceuticals, Inc. | 612.88 Million USD | -27.325% |
| Absci Corporation | 234.48 Million USD | -232.801% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -10567.82% |
| 4D Molecular Therapeutics, Inc. | 339.89 Million USD | -129.589% |
| Dyne Therapeutics, Inc. | 165.08 Million USD | -372.705% |
| Kiniksa Pharmaceuticals, Ltd. | 526.32 Million USD | -48.265% |
| Ventyx Biosciences, Inc. | 277.69 Million USD | -181.012% |
| Allakos Inc. | 243.61 Million USD | -220.328% |
| Imunon, Inc. | 21.91 Million USD | -3460.309% |
| Fulcrum Therapeutics, Inc. | 257.69 Million USD | -202.821% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | -25.556% |
| BioAtla, Inc. | 119.65 Million USD | -552.151% |
| NLS Pharmaceutics AG | 1.84 Million USD | -42157.862% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | -24134.503% |
| Allogene Therapeutics, Inc. | 642.83 Million USD | -21.392% |
| Larimar Therapeutics, Inc. | 95.93 Million USD | -713.416% |
| XOMA Corporation | 234.3 Million USD | -233.055% |
| Kezar Life Sciences, Inc. | 221.23 Million USD | -252.725% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -520.094% |
| aTyr Pharma, Inc. | 122.06 Million USD | -539.281% |
| Aligos Therapeutics, Inc. | 153.9 Million USD | -407.041% |
| Akero Therapeutics, Inc. | 580.27 Million USD | -34.48% |
| Viridian Therapeutics, Inc. | 490.42 Million USD | -59.118% |
| Eliem Therapeutics, Inc. | 110.46 Million USD | -606.398% |
| EyeGate Pharmaceuticals, Inc. | 15.15 Million USD | -5048.263% |
| Akari Therapeutics, Plc | 4.35 Million USD | -17818.507% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -4480.242% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 54.978% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -25203.325% |
| UroGen Pharma Ltd. | 178.31 Million USD | -337.635% |
| Sutro Biopharma, Inc. | 470.73 Million USD | -65.773% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | -140322.879% |
| Orgenesis Inc. | 14.55 Million USD | -5262.5% |
| Entera Bio Ltd. | 11.76 Million USD | -6532.818% |
| GH Research PLC | 226.3 Million USD | -244.83% |
| Lisata Therapeutics, Inc. | 54.69 Million USD | -1326.758% |
| Reneo Pharmaceuticals, Inc. | 107.43 Million USD | -626.34% |
| Xencor, Inc. | 952.69 Million USD | 18.09% |
| 60 Degrees Pharmaceuticals, Inc. | 7.78 Million USD | -9925.359% |
| Replimune Group, Inc. | 487.72 Million USD | -59.999% |
| Coeptis Therapeutics Holdings, Inc. | 8.07 Million USD | -9568.472% |
| Vanda Pharmaceuticals Inc. | 648.44 Million USD | -20.343% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -25203.325% |
| Portage Biotech Inc. | 7.77 Million USD | -9931.508% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -17387.386% |
| Olema Pharmaceuticals, Inc. | 276.94 Million USD | -181.771% |
| OncoCyte Corporation | 74.89 Million USD | -941.968% |
| Qualigen Therapeutics, Inc. | 2.03 Million USD | -38279.529% |
| Processa Pharmaceuticals, Inc. | 5.78 Million USD | -13385.383% |
| Purple Biotech Ltd. | 44.3 Million USD | -1661.435% |
| CollPlant Biotechnologies Ltd. | 34.12 Million USD | -2186.676% |
| scPharmaceuticals Inc. | 94.47 Million USD | -725.952% |
| ProMIS Neurosciences, Inc. | 18.04 Million USD | -4224.482% |
| HilleVax, Inc. | 344.43 Million USD | -126.56% |
| NeuroSense Therapeutics Ltd. | 3.17 Million USD | -24470.246% |
| Tharimmune, Inc. | 10.94 Million USD | -7028.841% |
| Genprex, Inc. | 10.67 Million USD | -7213.099% |
| Neumora Therapeutics, Inc. Common Stock | 496.19 Million USD | -57.267% |
| Atossa Therapeutics, Inc. | 96.25 Million USD | -710.737% |
| XTL Biopharmaceuticals Ltd. | 2.42 Million USD | -32066.158% |
| Virios Therapeutics, Inc. | 4.16 Million USD | -18633.935% |
| OKYO Pharma Limited | 1.54 Million USD | -50530.586% |
| Savara Inc. | 177.56 Million USD | -339.476% |
| Curis, Inc. | 77.28 Million USD | -909.745% |
| Daré Bioscience, Inc. | 21.28 Million USD | -3566.681% |
| Carmell Therapeutics Corporation | 63.94 Million USD | -1120.275% |
| Titan Pharmaceuticals, Inc. | 8.08 Million USD | -9550.643% |
| Achieve Life Sciences, Inc. | 19.37 Million USD | -3928.45% |
| BeiGene, Ltd. | 5.8 Billion USD | 86.558% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | -6312.614% |
| Revolution Medicines, Inc. Warrant | 2.08 Billion USD | 62.637% |
| Protagonist Therapeutics, Inc. | 357.95 Million USD | -118.005% |
| Erasca, Inc. | 395.29 Million USD | -97.409% |
| bluebird bio, Inc. | 619.16 Million USD | -26.034% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -17949.604% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 88.594% |
| DBV Technologies S.A. | 182.98 Million USD | -326.454% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -17949.604% |
| Moderna, Inc. | 18.42 Billion USD | 95.765% |
| Vincerx Pharma, Inc. | 18.21 Million USD | -4183.642% |
| Fresh Tracks Therapeutics, Inc. | 11.58 Million USD | -6635.293% |
| Molecular Templates, Inc. | 35.38 Million USD | -2105.44% |
| Acrivon Therapeutics, Inc. Common Stock | 138.26 Million USD | -464.388% |
| Travere Therapeutics, Inc. | 788.91 Million USD | 1.085% |
| Monte Rosa Therapeutics, Inc. | 303.75 Million USD | -156.901% |
| Spruce Biosciences, Inc. | 103.94 Million USD | -650.727% |
| Celldex Therapeutics, Inc. | 465.62 Million USD | -67.591% |
| Cogent Biosciences, Inc. | 313.43 Million USD | -148.966% |
| MacroGenics, Inc. | 306.82 Million USD | -154.335% |
| RenovoRx, Inc. | 1.46 Million USD | -53129.945% |
| Adicet Bio, Inc. | 207.29 Million USD | -276.445% |
| Prime Medicine, Inc. | 193.85 Million USD | -302.552% |
| Aditxt, Inc. | 44.57 Million USD | -1650.517% |
| Adagene Inc. | 115.72 Million USD | -574.293% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -17419.486% |
| Quantum-Si incorporated | 298.25 Million USD | -161.643% |
| Maravai LifeSciences Holdings, Inc. | 1.48 Billion USD | 47.538% |
| Acurx Pharmaceuticals, Inc. | 7.7 Million USD | -10022.435% |
| Voyager Therapeutics, Inc. | 351.28 Million USD | -122.144% |
| SciSparc Ltd. | 11.18 Million USD | -6878.635% |
| Vericel Corporation | 353.65 Million USD | -120.652% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -6289.716% |
| Minerva Neurosciences, Inc. | 56.9 Million USD | -1271.428% |
| Generation Bio Co. | 374.75 Million USD | -108.228% |
| Astria Therapeutics, Inc. | 254.66 Million USD | -206.421% |
| Black Diamond Therapeutics, Inc. | 158.56 Million USD | -392.127% |
| Arcutis Biotherapeutics, Inc. | 341.36 Million USD | -128.597% |
| Invivyd, Inc. | 229.18 Million USD | -240.496% |
| Relay Therapeutics, Inc. | 843.98 Million USD | 7.539% |
| Quoin Pharmaceuticals, Ltd. | 12.16 Million USD | -6312.455% |
| Spero Therapeutics, Inc. | 182.39 Million USD | -327.847% |
| Artelo Biosciences, Inc. | 20.42 Million USD | -3720.755% |
| 2seventy bio, Inc. | 565.42 Million USD | -38.011% |
| ADMA Biologics, Inc. | 329.18 Million USD | -137.058% |
| Clene Inc. | 52.34 Million USD | -1390.898% |
| Capricor Therapeutics, Inc. | 58.73 Million USD | -1228.611% |
| Boundless Bio, Inc. Common Stock | 129.89 Million USD | -500.76% |
| GeoVax Labs, Inc. | 9.28 Million USD | -8306.039% |
| Recursion Pharmaceuticals, Inc. | 653.69 Million USD | -19.375% |
| Citius Pharmaceuticals, Inc. | 103.61 Million USD | -653.153% |
| Contineum Therapeutics, Inc. Class A Common Stock | 130.38 Million USD | -498.493% |
| Relmada Therapeutics, Inc. | 97.55 Million USD | -699.933% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | -999.132% |
| ALX Oncology Holdings Inc. | 242.55 Million USD | -221.724% |
| Vir Biotechnology, Inc. | 1.96 Billion USD | 60.188% |
| Evaxion Biotech A/S | 12.88 Million USD | -5954.574% |
| Ocular Therapeutix, Inc. | 252.06 Million USD | -209.589% |
| Verve Therapeutics, Inc. | 752.68 Million USD | -3.675% |
| Trevena, Inc. | 40.6 Million USD | -1821.81% |
| Surrozen, Inc. | 46.08 Million USD | -1593.47% |
| Tyra Biosciences, Inc. | 225.85 Million USD | -245.507% |
| Cingulate Inc. | 3.49 Million USD | -22250.431% |
| Galmed Pharmaceuticals Ltd. | 16.62 Million USD | -4592.712% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -1087.93% |
| Tenax Therapeutics, Inc. | 11.68 Million USD | -6578.442% |
| Terns Pharmaceuticals, Inc. | 268.51 Million USD | -190.615% |
| ACADIA Pharmaceuticals Inc. | 748.95 Million USD | -4.192% |
| Connect Biopharma Holdings Limited | 125.89 Million USD | -519.857% |
| Clearmind Medicine Inc. | 4.32 Million USD | -17945.347% |
| Kronos Bio, Inc. | 213.27 Million USD | -265.883% |
| Bolt Biotherapeutics, Inc. | 159.78 Million USD | -388.379% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -9015.6% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -111.77% |
| Statera Biopharma, Inc. | 21.16 Million USD | -3586.172% |
| ImmunityBio, Inc. | 504.45 Million USD | -54.693% |
| Korro Bio, Inc. | 221.66 Million USD | -252.044% |
| Kineta, Inc. | 10.28 Million USD | -7490.225% |
| BioVie Inc. | 25.2 Million USD | -2995.606% |
| Codexis, Inc. | 136.56 Million USD | -471.43% |
| Celularity Inc. | 143.88 Million USD | -442.328% |
| Crinetics Pharmaceuticals, Inc. | 635.35 Million USD | -22.822% |
| Celcuity Inc. | 191.21 Million USD | -308.092% |
| Virax Biolabs Group Limited | 5.48 Million USD | -14129.676% |
| Cibus, Inc. | 544.41 Million USD | -43.339% |
| Eledon Pharmaceuticals, Inc. | 125.89 Million USD | -519.848% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | -3698.438% |
| IN8bio, Inc. | 33.7 Million USD | -2214.963% |
| Kodiak Sciences Inc. | 479.37 Million USD | -62.786% |
| Annexon, Inc. | 297.67 Million USD | -162.15% |
| Adverum Biotechnologies, Inc. | 173.01 Million USD | -351.044% |
| Assembly Biosciences, Inc. | 137.46 Million USD | -467.656% |
| Avalo Therapeutics, Inc. | 20.99 Million USD | -3617.196% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 73.902% |
| Eyenovia, Inc. | 28.77 Million USD | -2611.494% |
| Puma Biotechnology, Inc. | 230.52 Million USD | -238.506% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -10702.201% |
| Xilio Therapeutics, Inc. | 60.92 Million USD | -1180.818% |
| Arcellx, Inc. | 825.13 Million USD | 5.427% |
| Cardiff Oncology, Inc. | 81.63 Million USD | -855.879% |
| Enanta Pharmaceuticals, Inc. | 462.27 Million USD | -68.807% |
| Regulus Therapeutics Inc. | 30.75 Million USD | -2437.727% |
| Moolec Science SA | 24.05 Million USD | -3144.529% |
| Acumen Pharmaceuticals, Inc. | 310.12 Million USD | -151.625% |
| Geron Corporation | 394.07 Million USD | -98.02% |
| LAVA Therapeutics N.V. | 101.71 Million USD | -667.231% |
| Royalty Pharma plc | 16.38 Billion USD | 95.236% |
| Atea Pharmaceuticals, Inc. | 594.96 Million USD | -31.158% |
| Greenwich LifeSciences, Inc. | 6.99 Million USD | -11056.135% |
| TFF Pharmaceuticals, Inc. | 12.02 Million USD | -6388.156% |
| Mersana Therapeutics, Inc. | 226.06 Million USD | -245.196% |
| Humacyte, Inc. | 128.22 Million USD | -508.589% |
| Structure Therapeutics Inc. | 482.01 Million USD | -61.893% |
| 89bio, Inc. | 596.26 Million USD | -30.872% |
| PMV Pharmaceuticals, Inc. | 252.15 Million USD | -209.476% |
| Avenue Therapeutics, Inc. | 1.85 Million USD | -42081.135% |
| Genelux Corporation | 27.89 Million USD | -2697.659% |
| Trevi Therapeutics, Inc. | 89.4 Million USD | -772.847% |
| Lexicon Pharmaceuticals, Inc. | 229.42 Million USD | -240.127% |
| Notable Labs, Ltd. | 19.54 Million USD | -3893.404% |
| Liquidia Corporation | 120.43 Million USD | -547.965% |
| Mustang Bio, Inc. | 17.74 Million USD | -4298.326% |
| Immunovant, Inc. | 666.71 Million USD | -17.045% |
| Quantum-Si incorporated | 298.25 Million USD | -161.643% |
| Arbutus Biopharma Corporation | 144.4 Million USD | -440.406% |
| DiaMedica Therapeutics Inc. | 54.16 Million USD | -1340.825% |
| Vera Therapeutics, Inc. | 175.54 Million USD | -344.528% |
| Acasti Pharma Inc. | 73.3 Million USD | -964.599% |
| MiNK Therapeutics, Inc. | 4.55 Million USD | -17041.978% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -2887.921% |
| Xenon Pharmaceuticals Inc. | 964.79 Million USD | 19.118% |
| Elevai Labs, Inc. Common Stock | 5.18 Million USD | -14935.902% |
| NeuroBo Pharmaceuticals, Inc. | 22.78 Million USD | -3325.447% |
| Tempest Therapeutics, Inc. | 51.6 Million USD | -1412.22% |
| Soleno Therapeutics, Inc. | 180.69 Million USD | -331.87% |
| PepGen Inc. | 143.05 Million USD | -445.502% |
| Moleculin Biotech, Inc. | 38.21 Million USD | -1941.895% |
| United Therapeutics Corporation | 7.16 Billion USD | 89.112% |
| Nuvectis Pharma, Inc. | 19.18 Million USD | -3967.506% |
| Solid Biosciences Inc. | 164.93 Million USD | -373.115% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -13188.766% |
| Immuneering Corporation | 102.58 Million USD | -660.691% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -18011.391% |
| Silo Pharma, Inc. | 7.74 Million USD | -9974.061% |
| Belite Bio, Inc | 94.64 Million USD | -724.529% |
| XOMA Corporation | 234.3 Million USD | -233.055% |
| ARS Pharmaceuticals, Inc. | 233.18 Million USD | -234.645% |
| Bionomics Limited | 27.64 Million USD | -2722.339% |
| Apogee Therapeutics, Inc. | 401.4 Million USD | -94.405% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -626.665% |
| uniQure N.V. | 831.68 Million USD | 6.173% |
| Cassava Sciences, Inc. | 151.66 Million USD | -414.53% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -17419.486% |
| Poseida Therapeutics, Inc. | 273.88 Million USD | -184.919% |
| Forte Biosciences, Inc. | 38.98 Million USD | -1901.927% |
| Anebulo Pharmaceuticals, Inc. | 4.07 Million USD | -19058.585% |
| Enlivex Therapeutics Ltd. | 36.83 Million USD | -2018.734% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -10702.201% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -22113.237% |
| FibroBiologics, Inc. Common Stock | 11.82 Million USD | -6501.396% |
| Altimmune, Inc. | 210.64 Million USD | -270.467% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | -0.318% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -626.665% |
| Compugen Ltd. | 121.33 Million USD | -543.143% |
| Peak Bio, Inc. | 2.59 Million USD | -29954.941% |
| Zevra Therapeutics, Inc. | 172.32 Million USD | -352.832% |
| Benitec Biopharma Inc. | 52.21 Million USD | -1394.639% |
| Spyre Therapeutics, Inc. | 341.85 Million USD | -128.267% |
| NKGen Biotech, Inc. Common Stock | 34.77 Million USD | -2144.129% |
| Zura Bio Limited | 100.84 Million USD | -673.828% |
| PolyPid Ltd. | 15.37 Million USD | -4976.444% |
| Aileron Therapeutics, Inc. | 119.28 Million USD | -554.185% |
| NKGen Biotech, Inc. Warrants | 34.77 Million USD | -2144.129% |
| Instil Bio, Inc. | 325.63 Million USD | -139.643% |
| argenx SE | 4.54 Billion USD | 82.821% |
| Immunome, Inc. | 148.54 Million USD | -425.347% |
| Compass Therapeutics, Inc. | 156.87 Million USD | -397.435% |
| Verona Pharma plc | 308.12 Million USD | -153.259% |
| enGene Holdings Inc. Warrants | 86.95 Million USD | -797.378% |
| Shattuck Labs, Inc. | 159.56 Million USD | -389.052% |
| CervoMed Inc. | 9.97 Million USD | -7725.012% |
| LENZ Therapeutics, Inc. | 188.45 Million USD | -314.076% |
| Plus Therapeutics, Inc. | 11.38 Million USD | -6752.397% |
| Dianthus Therapeutics, Inc. | 179.4 Million USD | -334.966% |
| Moolec Science SA | 24.05 Million USD | -3144.529% |
| Enveric Biosciences, Inc. | 6.11 Million USD | -12656.086% |
| Inovio Pharmaceuticals, Inc. | 172.94 Million USD | -351.215% |
| AnaptysBio, Inc. | 452.38 Million USD | -72.496% |
| Design Therapeutics, Inc. | 289.64 Million USD | -169.418% |
| Leap Therapeutics, Inc. | 72.82 Million USD | -971.543% |
| NeurAxis, Inc. | 509.49 Thousand USD | -153060.758% |
| Seelos Therapeutics, Inc. | 5.41 Million USD | -14302.935% |
| Lumos Pharma, Inc. | 40.63 Million USD | -1820.25% |
| Achilles Therapeutics plc | 161.45 Million USD | -383.321% |
| enGene Holdings Inc. Common Stock | 86.95 Million USD | -797.378% |
| 180 Life Sciences Corp. | 5.25 Million USD | -14737.048% |
| Opiant Pharmaceuticals, Inc. | 70.42 Million USD | -1008.016% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -9015.6% |
| Nutriband Inc. | 7.51 Million USD | -10280.937% |
| ORIC Pharmaceuticals, Inc. | 254.68 Million USD | -206.397% |
| CG Oncology, Inc. Common stock | 199.3 Million USD | -291.544% |
| Fractyl Health, Inc. Common Stock | 76.21 Million USD | -923.921% |
| Rani Therapeutics Holdings, Inc. | 57.91 Million USD | -1247.384% |
| MoonLake Immunotherapeutics | 526.54 Million USD | -48.204% |
| Palisade Bio, Inc. | 14.05 Million USD | -5453.309% |
| Tourmaline Bio, Inc. | 210.29 Million USD | -271.074% |
| Beam Therapeutics Inc. | 1.45 Billion USD | 46.541% |
| Neurogene Inc. | 222.57 Million USD | -250.605% |
| Mirum Pharmaceuticals, Inc. | 646.62 Million USD | -20.681% |
| AEON Biopharma, Inc. | 6.84 Million USD | -11300.307% |
| CARGO Therapeutics, Inc. Common Stock | 453.03 Million USD | -72.249% |
| Sesen Bio, Inc. | 189.17 Million USD | -312.504% |
| Enliven Therapeutics, Inc. | 271.86 Million USD | -187.034% |
| Kiora Pharmaceuticals, Inc. | 13.71 Million USD | -5591.062% |
| Taysha Gene Therapies, Inc. | 266.99 Million USD | -192.273% |
| Athira Pharma, Inc. | 160.24 Million USD | -386.974% |
| Vaccinex, Inc. | 3.63 Million USD | -21391.352% |
| HCW Biologics Inc. | 28.51 Million USD | -2636.762% |
| XOMA Corporation | 234.3 Million USD | -233.055% |
| Nektar Therapeutics | 398.03 Million USD | -96.052% |
| Arvinas, Inc. | 1.3 Billion USD | 40.185% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -4480.242% |
| Merus N.V. | 458.49 Million USD | -70.199% |
| Omega Therapeutics, Inc. | 204.36 Million USD | -281.84% |
| Quince Therapeutics, Inc. | 180.2 Million USD | -333.038% |
| Rezolute, Inc. | 132.73 Million USD | -487.893% |
| Clene Inc. | 52.34 Million USD | -1390.898% |
| Indaptus Therapeutics, Inc. | 14.92 Million USD | -5128.875% |
| BeyondSpring Inc. | 24.8 Million USD | -3045.562% |
| Synlogic, Inc. | 75.55 Million USD | -932.893% |
| Allarity Therapeutics, Inc. | 11.86 Million USD | -6478.579% |
| Phio Pharmaceuticals Corp. | 9.36 Million USD | -8233.522% |
| Peak Bio, Inc. | 2.59 Million USD | -29954.941% |
| Werewolf Therapeutics, Inc. | 174.83 Million USD | -346.341% |
| Krystal Biotech, Inc. | 818.35 Million USD | 4.644% |
| Karyopharm Therapeutics Inc. | 240.43 Million USD | -224.554% |
| SpringWorks Therapeutics, Inc. | 725.78 Million USD | -7.518% |
| Lipella Pharmaceuticals Inc. | 3.57 Million USD | -21714.734% |
| MannKind Corporation | 475.19 Million USD | -64.216% |
| Ikena Oncology, Inc. | 192.09 Million USD | -306.238% |
| Cyclerion Therapeutics, Inc. | 13.37 Million USD | -5734.836% |
| Gyre Therapeutics, Inc. | 116.53 Million USD | -569.605% |
| Gossamer Bio, Inc. | 311.91 Million USD | -150.18% |
| CohBar, Inc. | 16.36 Million USD | -4668.22% |
| Cognition Therapeutics, Inc. | 35.16 Million USD | -2119.239% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -10567.82% |
| Legend Biotech Corporation | 1.84 Billion USD | 57.787% |
| Mural Oncology plc | 301.74 Million USD | -158.613% |
| Biora Therapeutics, Inc. | 31.21 Million USD | -2399.923% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | -13637.594% |
| Disc Medicine, Inc. | 367.99 Million USD | -112.054% |
| Champions Oncology, Inc. | 26.13 Million USD | -2886.189% |
| REGENXBIO Inc. | 573.97 Million USD | -35.957% |
| Ensysce Biosciences, Inc. | 2.7 Million USD | -28715.602% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -405.455% |
| Cellectar Biosciences, Inc. | 12.07 Million USD | -6362.224% |
| Edgewise Therapeutics, Inc. | 340.03 Million USD | -129.491% |
| Vaxart, Inc. | 91.83 Million USD | -749.778% |
| PharmaCyte Biotech, Inc. | 59.9 Million USD | -1202.672% |
| Aldeyra Therapeutics, Inc. | 148.32 Million USD | -426.102% |
| Cellectis S.A. | 334.27 Million USD | -133.449% |
| Longeveron Inc. | 12.17 Million USD | -6307.875% |
| Repare Therapeutics Inc. | 253.9 Million USD | -207.345% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 76.096% |
| Inozyme Pharma, Inc. | 200.84 Million USD | -288.53% |
| Revolution Medicines, Inc. | 2.08 Billion USD | 62.637% |
| Nymox Pharmaceutical Corporation | 1.62 Million USD | -47921.6% |
| Third Harmonic Bio, Inc. | 277.71 Million USD | -180.994% |
| ArriVent BioPharma, Inc. Common Stock | 163.09 Million USD | -378.455% |
| AN2 Therapeutics, Inc. | 138.74 Million USD | -462.439% |
| Anixa Biosciences, Inc. | 25.52 Million USD | -2957.562% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 96.567% |
| Denali Therapeutics Inc. | 1.15 Billion USD | 32.374% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -6289.716% |
| Veru Inc. | 50.59 Million USD | -1442.32% |
| Corvus Pharmaceuticals, Inc. | 45.55 Million USD | -1613.062% |
| Cingulate Inc. | 3.49 Million USD | -22250.431% |
| Passage Bio, Inc. | 150.54 Million USD | -418.351% |
| Context Therapeutics Inc. | 16.06 Million USD | -4758.145% |
| Exicure, Inc. | 11.58 Million USD | -6638.782% |
| Day One Biopharmaceuticals, Inc. | 376.04 Million USD | -107.514% |
| Oramed Pharmaceuticals Inc. | 161.64 Million USD | -382.765% |
| Scinai Immunotherapeutics Ltd. | 17.47 Million USD | -4366.295% |
| Rhythm Pharmaceuticals, Inc. | 332.74 Million USD | -134.519% |
| Nuvalent, Inc. | 732.38 Million USD | -6.549% |
| ABVC BioPharma, Inc. | 14.94 Million USD | -5121.807% |
| Carisma Therapeutics, Inc. | 89.55 Million USD | -771.375% |
| Unicycive Therapeutics, Inc. | 14.19 Million USD | -5398.915% |
| OmniAb, Inc. | 401.98 Million USD | -94.124% |
| Anew Medical, Inc. | 19.45 Million USD | -3910.86% |
| Fennec Pharmaceuticals Inc. | 26.72 Million USD | -2819.759% |
| Lipocine Inc. | 23 Million USD | -3292.672% |
| Lexeo Therapeutics, Inc. Common Stock | 139.8 Million USD | -458.163% |
| Nautilus Biotechnology, Inc. | 305.56 Million USD | -155.38% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -829.639% |
| G1 Therapeutics, Inc. | 121.54 Million USD | -542.053% |
| Bellerophon Therapeutics, Inc. | 7.93 Million USD | -9734.291% |
| Sage Therapeutics, Inc. | 882.27 Million USD | 11.553% |
| Ocugen, Inc. | 64.54 Million USD | -1108.966% |
| Mind Medicine (MindMed) Inc. | 124.54 Million USD | -526.582% |
| Q32 Bio Inc. | 306.11 Million USD | -154.918% |
| Brainstorm Cell Therapeutics Inc. | 4.2 Million USD | -18444.463% |
| Alumis Inc. Common Stock | 89.61 Million USD | -770.811% |
| Equillium, Inc. | 50.53 Million USD | -1444.332% |
| Kyverna Therapeutics, Inc. | 75.19 Million USD | -937.77% |
| Coya Therapeutics, Inc. | 41.27 Million USD | -1790.682% |
| CNS Pharmaceuticals, Inc. | 1.7 Million USD | -45779.979% |
| Galera Therapeutics, Inc. | 26.14 Million USD | -2885.161% |
| Evelo Biosciences, Inc. | 64.44 Million USD | -1110.954% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | -20837.144% |
| Dominari Holdings Inc. | 57.55 Million USD | -1255.765% |
| Edesa Biotech, Inc. | 8.89 Million USD | -8677.42% |
| vTv Therapeutics Inc. | 11.01 Million USD | -6982.51% |
| Bio-Techne Corporation | 2.81 Billion USD | 72.261% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | 16.729% |
| Harmony Biosciences Holdings, Inc. | 811.44 Million USD | 3.832% |
| Prelude Therapeutics Incorporated | 277.66 Million USD | -181.04% |
| Candel Therapeutics, Inc. | 41.7 Million USD | -1771.256% |
| iTeos Therapeutics, Inc. | 667.58 Million USD | -16.891% |
| Nkarta, Inc. | 378.88 Million USD | -105.96% |
| BioCardia, Inc. | 2.98 Million USD | -26024.908% |
| Iterum Therapeutics plc | 26.25 Million USD | -2871.747% |